Neurocrine Bio. (NBIX) PT Raised to $175 at Mizuho

Mizuho analyst Vamil Divan raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $175.00 (from $146.00) while maintaining a Neutral rating.

The analyst comments "We update our model and raise our PT to $175 from $146, primarily due to a higher sales forecast for Crenessity and extending its loss of exclusivity (LOE) from 2037 to 2040. Our Crenessity sales estimates of $120M for 4Q25 and $571M for 2026 are in line with Bloomberg consensus, but we project above-consensus sales beyond 2026. For Ingrezza, we maintain our below-consensus estimate of $657M (vs. $670M consensus) for 4Q25, as 4Q25 consensus does not appear to fully reflect one fewer selling week compared to 3Q25. For 2026 and beyond, our Ingrezza forecasts are largely aligned with consensus. Given the current stock price level, we maintain our Neutral rating on valuation and the absence of major catalysts in 2026."

You May Also Be Interested In

• Yesway Inc (YSWY) PT Raised to $32 at Guggenheim
• Spruce Biosciences, Inc. (SPRB) PT Lowered to $104 at Guggenheim
• Foghorn Therapeutics (FHTX) Reiterated at Buy by Stifel Amid Early Pipeline Excitement